Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US16651840Application Date: 2018-09-27
-
Publication No.: US11242348B2Publication Date: 2022-02-08
- Inventor: Makoto Kamata , Hideyuki Sugiyama , Minoru Nakamura , Masataka Murakami , Shuhei Ikeda , Tomohiro Okawa , Hidekazu Tokuhara
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JPJP2017-190838 20170929
- International Application: PCT/JP2018/035827 WO 20180927
- International Announcement: WO2019/065791 WO 20190404
- Main IPC: C07D487/10
- IPC: C07D487/10 ; A61P25/28 ; A61K9/20 ; A61K9/48

Abstract:
The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
Public/Granted literature
- US11274101B2 Heterocyclic compound Public/Granted day:2022-03-15
Information query